Johnson & Stricker lay down the law on how IDSA became entangled with antitrust.
21 May
Some more light reading for those late nights when nothing in on the tube and you're wondering how IDSA got ensnared in antitrust law with its Lyme disease guidelines.
Just how flawed was its guidelines development process?
Why is it important to democracy that opposing viewpoints be heard before vital freedoms--like your ability to choose among treatment options--are taken away.
When do medical society have an obligation to not suppress legitimate medical controversy?
And, what is the drill for the settlement process anyway?
If you have comments on the article, send them to me at [email protected]
i can't read TIMESNEWROMAN so have copied this brief article below and breaking it up for us neuros to read/comprehend.
If you have comments on the article, send them to me at [email protected] ***************************************
Journal of Medical Ethics 2009;35:283-288; doi:10.1136/jme.2008.026526
Copyright � 2009 by the BMJ Publishing Group Ltd & Institute of Medical Ethics.
Attorney General forces Infectious Diseases Society of America to redo Lyme guidelines due to flawed development process
1 California Lyme Disease Association, Ukiah, California, USA
2 International Lyme and Associated Diseases Society, Bethesda, Maryland, USA
Correspondence to:
Dr R B Stricker, 450 Sutter Street, Suite 1504, San Francisco, California 94108, USA; [email protected]
Lyme disease is one of the most controversial illnesses in the history of medicine.
In 2006 the Connecticut Attorney General launched an antitrust investigation into the Lyme guidelines development process of the Infectious Diseases Society of America (IDSA).
In a recent settlement with IDSA, the Attorney General noted important commercial conflicts of interest and suppression of scientific evidence that had tainted the guidelines process.
This paper explores two broad ethical themes that influenced the IDSA investigation.
The first is the growing problem of conflicts of interest among guidelines developers, and the second is the increasing centralisation of medical decisions by insurance companies, which use treatment guidelines as a means of controlling the practices of individual doctors and denying treatment for patients.
The implications of the first-ever antitrust investigation of medical guidelines and the proposed model to remediate the tainted IDSA guidelines process are also discussed.
**************
so their article did NOT show up; a brief summary? guess i'll email lorraine... betty
Posted by JKMMC09 (Member # 15795) on :
Tincup- is it possible to see the full article on CALDA's website, I can't seem to find it... Thanks!
Posted by Tincup (Member # 5829) on :
JK..
I couldn't find the original article either... so I wrote to the authors and asked if it was somewhere (point it out) and could they direct me to it so it can be shared.
If so, will do!
Posted by Tincup (Member # 5829) on :
Just heard back. It is copy righted.
Sorry!!!!!
Posted by radfaraf (Member # 11909) on :
btw, that site does not render correctly in IE 8, best to use firefox, google chrome, or an earlier verison of IE with it.
Posted by bettyg (Member # 6147) on :
it can be purchased from the site shown above ... british .....
![[Big Grin]](biggrin.gif)